Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
Spero Therapeutics (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on developing treatments for rare diseases and multi-drug resistant bacterial infections, has announced its participation in the TD Cowen 45th Annual Health Care Conference.
The conference will be held in Boston from March 3-5, 2025, where Esther Rajavelu, Spero's Interim President and CEO, will present and be available for one-on-one meetings with interested parties.
Those interested in scheduling meetings can contact their institutional representative or email for details. A webcast of the presentation will be accessible through Spero Therapeutics' website on the "Events and Presentations" page under the "Connect" tab, with a replay available after the event concludes.
Spero Therapeutics (Nasdaq: SPRO), una società biofarmaceutica clinica multi-asset focalizzata sullo sviluppo di trattamenti per malattie rare e infezioni batteriche multi-resistenti, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Salute di TD Cowen.
La conferenza si terrà a Boston dal 3 al 5 marzo 2025, dove Esther Rajavelu, Presidente e CEO ad interim di Spero, presenterà e sarà disponibile per incontri individuali con le parti interessate.
Coloro che sono interessati a programmare incontri possono contattare il proprio rappresentante istituzionale o inviare un'email per ulteriori dettagli. Una trasmissione in diretta della presentazione sarà accessibile attraverso il sito web di Spero Therapeutics nella pagina
Spero Therapeutics (Nasdaq: SPRO), una compañía biofarmacéutica en etapa clínica con múltiples activos, centrada en el desarrollo de tratamientos para enfermedades raras e infecciones bacterianas multirresistentes, ha anunciado su participación en la 45ª Conferencia Anual de Salud de TD Cowen.
La conferencia se llevará a cabo en Boston del 3 al 5 de marzo de 2025, donde Esther Rajavelu, Presidenta y CEO interina de Spero, presentará y estará disponible para reuniones individuales con las partes interesadas.
Los interesados en programar reuniones pueden contactar a su representante institucional o enviar un correo electrónico para más detalles. Una transmisión en vivo de la presentación estará disponible a través del sitio web de Spero Therapeutics en la página de
Spero Therapeutics (Nasdaq: SPRO), 희귀 질환 및 다제내성 세균 감염 치료제 개발에 중점을 둔 다중 자산 임상 단계 생명공학 회사가 TD Cowen 제45회 연례 건강 관리 회의에 참여한다고 발표했습니다.
회의는 2025년 3월 3일부터 5일까지 보스턴에서 개최되며, Esther Rajavelu Spero의 임시 회장 겸 CEO가 발표를 하고 관심 있는 당사자와의 일대일 회의에 참석할 예정입니다.
회의 일정을 잡고자 하는 분들은 소속 기관의 대표에게 연락하시거나 이메일로 자세한 내용을 문의하실 수 있습니다. 발표의 웹캐스트는 Spero Therapeutics 웹사이트의
Spero Therapeutics (Nasdaq: SPRO), une société biopharmaceutique en phase clinique avec plusieurs actifs, axée sur le développement de traitements pour les maladies rares et les infections bactériennes multirésistantes, a annoncé sa participation à la 45e Conférence Annuelle de Santé de TD Cowen.
La conférence se tiendra à Boston du 3 au 5 mars 2025, où Esther Rajavelu, Présidente et PDG par intérim de Spero, présentera et sera disponible pour des réunions individuelles avec les parties intéressées.
Les personnes intéressées à programmer des réunions peuvent contacter leur représentant institutionnel ou envoyer un e-mail pour plus de détails. Un webinaire de la présentation sera accessible via le site web de Spero Therapeutics sur la page
Spero Therapeutics (Nasdaq: SPRO), ein biopharmazeutisches Unternehmen in der klinischen Phase mit mehreren Vermögenswerten, das sich auf die Entwicklung von Behandlungen für seltene Krankheiten und multiresistente bakterielle Infektionen konzentriert, hat seine Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen angekündigt.
Die Konferenz findet vom 3. bis 5. März 2025 in Boston statt, wo Esther Rajavelu, Interim-Präsidentin und CEO von Spero, präsentieren und für Einzelgespräche mit interessierten Parteien zur Verfügung stehen wird.
Interessierte, die Meetings vereinbaren möchten, können ihren institutionellen Vertreter kontaktieren oder eine E-Mail für weitere Details senden. Ein Webcast der Präsentation wird auf der Website von Spero Therapeutics auf der Seite
- None.
- None.
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu, Spero’s Interim President and Chief Executive Officer, management will present and will be available for one-on-one meetings at the TD Cowen 45th Annual Health Care Conference being held in Boston, March 3rd – 5th, 2025. Details are as follows:
| TD Cowen 45th Annual Health Care Conference | ||
| Company presentation: | Wednesday March 5, 2025 | |
| Time: | 3:10 PM ET | |
To request a meeting or for more details about the conferences please reach out to your institutional contact or email.
The webcast may also be accessed through Spero Therapeutics’ website (www.sperotherapeutics.com) on the “Events and Presentations” page under the “Connect” tab. A replay will be available on the website following the conclusion of the event.
About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial infections.
For more information, visit https://sperotherapeutics.com.
Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@Sperotherapeutics.com
Media Inquiries: media@sperotherapeutics.com
FAQ
When is Spero Therapeutics (SPRO) presenting at the TD Cowen Health Care Conference?
Who will represent Spero Therapeutics (SPRO) at the 2025 TD Cowen conference?
How can investors access Spero Therapeutics' (SPRO) presentation at the TD Cowen conference?
What therapeutic areas does Spero Therapeutics (SPRO) focus on?
How can investors arrange one-on-one meetings with Spero Therapeutics (SPRO) management at the TD Cowen conference?
